JAMES CASE: Open Payments
NPI 1457816035 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$225 in 10 payments from 8 companies in 2025. Trend: 2023 $117 · 2024 $189 · 2025 $225
Food & beverage: $225
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| REVANCE THERAPEUTICS, INC. | 1 | $36 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: CAPLYTA, DAXXIFY, INJECTAFER, Kerendia, VOQUEZNA, Rybelsus, AUSTEDO XR, FARXIGA.
Industry payments across WA — which companies pay providers there.
